Five years ago, Biogen’s stock briefly traded above $425 on the back of an Alzheimer’s drug that Medicare ultimately refused to cover. Today the stock sits near $218, the drug is gone, and a new CEO has spent three years rebuilding around a different Alzheimer’s treatment, a rare-disease portfolio, and a multibillion-dollar acquisition. The question the price is quietly asking: has the rebuild actually arrived in the income statement?
Here is the tension. The stock’s price-to-earnings multiple, a ratio that tells you how many dollars investors pay for each dollar of annual profit, sits at 25 times earnings, our data show. Biogen’s own decade-long median multiple is 18.6 times. That gap means the market is paying an 80th-percentile premium for a company whose trailing net profit margin as of the Q2 2026 filing has compressed to roughly 8%, down from more than 15% a year earlier. Premium price, shrinking margin. Those two facts should not coexist without a very good explanation.
What matters here
The filed numbers show Biogen’s net margin has been cut nearly in half over the past year, even as revenue has started growing again. The current stock price embeds a multiple that historically only appeared when Biogen’s profitability was expanding, not contracting. The open question is whether the Apellis acquisition and the Alzheimer’s franchise can restore margins fast enough to justify what the market is already paying.
How the company got here
For most of its history, Biogen was a multiple sclerosis company. Drugs like Tysabri and Tecfidera generated margins that were the envy of the industry, and the stock was priced accordingly. Then two things happened at once: MS patents began expiring, and management made a decade-long bet on Alzheimer’s disease that nearly broke the company.
The FDA’s accelerated approval of Aduhelm in June 2021 sent the stock past $425 in a single session. Within months, the drug’s steep price tag drew congressional hearings, and by April 2022 Medicare had limited coverage to clinical trials only. Biogen discontinued Aduhelm entirely in January 2024. The episode cost the company years of R&D capital and management credibility.
CEO Christopher Viehbacher arrived in November 2022 and immediately launched what the company calls “Fit for Growth,” a drive to cut a substantial portion of annual operating costs by the end of 2025. The 10-K filed in February 2026 shows the result: full-year 2025 revenue of $9.9 billion, the first year of growth after three straight years of decline. The cost program appears to have worked. The margin question is what happened next.
What the filings say the margin actually is
Revenue growing is not the same as profit growing. The Q2 2026 10-Q shows a trailing net margin of roughly 8%, compared to 15% a year earlier. The culprit is acquisition accounting. Biogen closed its purchase of Apellis Pharmaceuticals, and the deal carried meaningful non-GAAP earnings dilution for the full year, according to the company’s own updated guidance. On top of that, acquired in-process R&D charges, the accounting cost of buying drugs still in development, ran to about $164 million in Q2 alone, with hundreds of millions more projected for Q3.
Think of it this way: Biogen bought several promising drugs that haven’t launched yet, and accounting rules require it to expense much of that purchase price immediately, even though the revenue from those drugs may be years away. A household analogy: paying full tuition today for a degree that won’t generate income for three years. The cash is real; the future income is not yet.
The result is that Biogen’s own updated 2026 non-GAAP EPS guidance, issued in July 2026, came in well below the range the company had set at the start of the year. At $218 per share, investors are paying a price that sounds reasonable against the company’s adjusted profit estimate until you notice the GAAP margin is closer to 8%, which at the current price implies a multiple closer to 25 times filed earnings, our data show.
What the growth portfolio is actually delivering
The bull case rests on one concrete shift: for the second consecutive quarter, Biogen’s growth portfolio, anchored by the Alzheimer’s drug LEQEMBI and the rare-disease drug SKYCLARYS, generated more revenue than its legacy MS franchise. The Q2 2026 filing shows the growth portfolio at $1.06 billion for the quarter, edging past the MS drugs. That crossover matters because MS revenue is structurally declining as older drugs face generic competition, and the growth portfolio is the only engine that can replace it.
LEQEMBI received an additional FDA approval in July 2026 for a once-weekly subcutaneous injection, meaning patients can now administer it at home rather than through an IV infusion at a clinic. That removes a significant adoption barrier. The subcutaneous version became available in the U.S. in late August 2026, per MarketBeat’s FDA events tracker. CEO Viehbacher stated in July 2026, as reported by Reuters via StreetInsider, that the growth portfolio is now sufficient to return Biogen to a growth trajectory. Whether “sufficient” translates into margin recovery is the unanswered part.
The margin the price assumes
Our data put Biogen’s current P/E at 25.2 times, at the 80th percentile of its own decade. Historically, Biogen traded at that kind of premium when its net margin was running above 20%. The filed margin today is less than half that. For the premium to be justified by the math rather than the mood, margins would need to roughly double from their current level.
That path exists on paper. The Apellis acquisition charges are largely front-loaded; the company’s own guidance implies they ease after Q3 2026. The pipeline page lists ten programs in Phase 3, including zorevunersen for Dravet syndrome, a severe childhood epilepsy with no approved disease-modifying treatment. If several of those programs reach approval and the Apellis drugs ramp, the margin arithmetic could close. But “could close” is not the same as “has closed,” and the price is behaving as if it already has.
If earnings land at the high end of Biogen’s own guidance and the multiple compresses to its decade median, the math would point toward a price meaningfully below today’s level. If margins recover toward the 20% range and the multiple holds near current levels, the math runs the other direction. The data cannot tell us which scenario arrives; they can only tell us the current price leaves little room for the first one.
Reading the numbers
- Net margin, trailing twelve months: ~8%. This is what Biogen keeps from each dollar of sales after all costs, taxes, and acquisition charges. A year ago it was roughly 15%. The compression is almost entirely acquisition-driven, which means it could reverse, but it hasn’t yet. A business earning 8 cents on the dollar, priced as if it earns 20, is a gap worth watching.
- P/E of 25.2 vs. decade median of 18.6. The P/E is the price per dollar of annual profit. At 25.2, investors are paying $25 for every $1 of filed earnings. The decade median says Biogen normally trades at $18.60 per dollar. That $6.40 premium per dollar of profit, multiplied across the whole company, represents a very large bet on margin recovery. A household analogy: paying $250 for a piece of furniture that normally sells for $186, because you expect the store to renovate.
- 2026 non-GAAP EPS guidance: $12.00 to $13.00. This is the company’s own estimate of per-share profit, excluding acquisition charges. Analyst consensus sits at $13.17, per MarketBeat, slightly above the top of management’s range. At $218 per share, that implies investors are paying roughly 17 to 18 times the company’s own best-case non-GAAP number, and 25 times the GAAP number. Both figures are above the decade median.
- Q3 2026 projected acquisition charges: $290 million to $320 million. This is a near-term headwind that the market appears to have already priced through. If it hasn’t, the next quarterly filing could be a reset moment.
For the standing yardsticks on Biogen: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Biogen.
Sources
- Biogen 10-Q, Q2 2026 (SEC EDGAR)
- Biogen 10-K, FY2025 (SEC EDGAR)
- Biogen 10-K, FY2024 (SEC EDGAR)
- Reuters via StreetInsider: Biogen beats Q2 estimates
- MarketBeat: BIIB analyst forecasts
- MarketBeat: BIIB FDA events
- Biogen pipeline page
- Los Angeles Times: Biogen cuts Aduhelm price
- Seeking Alpha: Biogen Q2 beat and 2026 outlook update
- StockTitan: Biogen 8-K material event (Apellis acquisition)
